Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IPSEY NASDAQ:ONC OTCMKTS:SDZNY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPSEYIPSEN$32.22$30.35$25.11▼$33.00$10.80B0.5448 shs156 shsONCBeOne Medicines$299.01-0.7%$263.99$155.75▼$308.87$33.00B0.27402,877 shs543,060 shsSDZNYSandoz Group$56.990.0%$54.42$35.61▼$60.69$25.08B0.620,637 shs20,766 shsSMMTSummit Therapeutics$27.07+2.7%$23.35$8.88▼$36.91$19.58B-1.062.68 million shs1.92 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPSEYIPSEN0.00%-0.62%+7.36%+8.89%+13.75%ONCBeOne Medicines-0.70%+2.59%+22.38%+16.91%+29,900,999,900.00%SDZNYSandoz Group-0.04%-4.09%+5.65%+28.30%+31.24%SMMTSummit Therapeutics+2.65%-5.58%+19.67%-2.97%+150.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIPSEYIPSENN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines0.7112 of 5 stars1.50.00.00.01.91.70.6SDZNYSandoz Group1.6212 of 5 stars0.03.00.80.01.70.02.5SMMTSummit Therapeutics3.0125 of 5 stars4.42.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPSEYIPSEN 3.00BuyN/AN/AONCBeOne Medicines 3.00Buy$327.569.55% UpsideSDZNYSandoz Group 2.00HoldN/AN/ASMMTSummit Therapeutics 2.79Moderate Buy$34.6728.06% UpsideCurrent Analyst Ratings BreakdownLatest IPSEY, ONC, SDZNY, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$321.00 ➝ $345.007/16/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$311.00 ➝ $349.007/1/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.007/1/2025SMMTSummit TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.006/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPSEYIPSEN$3.87B2.79N/AN/AN/A∞ONCBeOne Medicines$3.81B8.60N/AN/A$34.10 per share8.77SDZNYSandoz Group$10.36B2.42$2.67 per share21.33$18.56 per share3.07SMMTSummit Therapeutics$700K28,720.11N/AN/A$0.53 per share51.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPSEYIPSEN$374.30MN/A0.0011.19N/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A421.14N/A-9.40%-7.55%-4.42%8/6/2025 (Confirmed)SDZNYSandoz Group$1MN/A0.0017.170.99N/AN/AN/A8/7/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest IPSEY, ONC, SDZNY, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025SMMTSummit Therapeutics-$0.10N/AN/AN/AN/AN/A5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPSEYIPSEN$0.260.81%N/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ASDZNYSandoz Group$0.440.77%N/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest IPSEY, ONC, SDZNY, and SMMT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/3/2025IPSEYIPSEN$0.28960.97%6/9/20256/10/20256/25/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPSEYIPSENN/A1.341.15ONCBeOne Medicines0.051.961.71SDZNYSandoz Group0.571.240.79SMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPSEYIPSENN/AONCBeOne Medicines48.55%SDZNYSandoz Group0.06%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipIPSEYIPSENN/AONCBeOne Medicines6.62%SDZNYSandoz GroupN/ASMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPSEYIPSEN5,358335.26 millionN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/ASDZNYSandoz Group23,406440.00 millionN/ANot OptionableSMMTSummit Therapeutics110742.67 million112.14 millionOptionableIPSEY, ONC, SDZNY, and SMMT HeadlinesRecent News About These CompaniesTD Asset Management Inc Reduces Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)July 31 at 4:51 AM | marketbeat.comSummit Therapeutics (SMMT) Projected to Post Earnings on TuesdayJuly 30 at 8:48 AM | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $1.28 Million Position in Summit Therapeutics PLC (NASDAQ:SMMT)July 30 at 6:12 AM | marketbeat.comTrivest Advisors Ltd Acquires New Position in Summit Therapeutics PLC (NASDAQ:SMMT)July 29, 2025 | marketbeat.comSummit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90July 28, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 27, 2025 | prnewswire.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives $34.67 Average Price Target from AnalystsJuly 27, 2025 | americanbankingnews.comIvyRock Asset Management HK Ltd Sells 74,759 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)July 26, 2025 | marketbeat.comLegato Capital Management LLC Takes Position in Summit Therapeutics PLC (NASDAQ:SMMT)July 26, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 22, 2025 | prnewswire.com3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial ResultsJuly 22, 2025 | fool.comThis Healthcare Stock's Revolutionary Drug Could Make Early Investors RichJuly 21, 2025 | finance.yahoo.comSargent Investment Group LLC Sells 70,000 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)July 21, 2025 | marketbeat.comKingsview Wealth Management LLC Buys Shares of 46,337 Summit Therapeutics PLC (NASDAQ:SMMT)July 21, 2025 | marketbeat.com3 Monster Stocks in the Making to Buy Right NowJuly 20, 2025 | fool.comPrincipal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)July 18, 2025 | marketbeat.comSMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law FirmJuly 17, 2025 | tmcnet.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 17, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?July 16, 2025 | marketbeat.comFlorida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)July 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?Palantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationThese 3 Dividend Stocks Are Not Concerned With Tariff NoiseBy Thomas Hughes | July 11, 2025View These 3 Dividend Stocks Are Not Concerned With Tariff NoisePEGA Surges 14%: There's Still Time to Ride This GenAI InnovatorBy Leo Miller | July 27, 2025View PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsBy Nathan Reiff | July 20, 2025View 3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsIPSEY, ONC, SDZNY, and SMMT Company DescriptionsIPSEN OTCMKTS:IPSEY$32.22 0.00 (0.00%) As of 07/31/2025Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.BeOne Medicines NASDAQ:ONC$299.01 -2.12 (-0.70%) As of 08/1/2025 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Sandoz Group OTCMKTS:SDZNY$56.99 -0.02 (-0.04%) As of 08/1/2025 03:51 PM EasternSandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.Summit Therapeutics NASDAQ:SMMT$27.07 +0.70 (+2.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$27.35 +0.28 (+1.03%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
